DYNDyne Therapeutics, Inc.

$3B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$30M

Net Income

-$30M

EPS (Diluted)

$-0.58

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$46M

Free Cash Flow

-$47M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$467M

Total Liabilities

$15M

Stockholders' Equity

$453M

Cash & Equivalents

$258M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$30M	-$9M	-247.7%
Net Income	-$30M	-$9M	-233.5%

DYN Q2 2021 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena